Search research articles

ACERCA DE JoVE

Visión General Liderazgo Blog Centro de Ayuda JoVE

AUTORES

Proceso de Publicación Consejo Editorial Alcance y Políticas Revisión por Pares Preguntas Frecuentes Enviar

BIBLIOTECARIOS

Testimonios Suscripciones Acceso Recursos Consejo Asesor de Bibliotecas Preguntas Frecuentes

INVESTIGACIÓN

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archivo

EDUCACIÓN

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Centro de Recursos para Profesores Sitio de Profesores

Términos y Condiciones de Uso

Política de Privacidad

Videos de Conceptos Relacionados

Additional Routes of Drug Administration

Additional Routes of Drug Administration

Choosing the appropriate route of drug administration is significantly influenced by two key factors: the therapeutic objectives and the inherent properties of the drug being used.
Administering drugs via inhalation allows for the direct delivery of gaseous, volatile substances or droplets to different parts of the respiratory tract. One of the advantages of the inhalation route is the rapid absorption of drugs into the circulatory system, which is possible because of the large surface area of...

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

Inhaled Medications

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...

Drug Delivery: Miscellaneous Routes

Drug Delivery: Miscellaneous Routes

Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...

Bioavailability: Influencing Factors

Bioavailability: Influencing Factors

Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por

Same author

Respiratory virus infections in decedents in a large, urban medical examiner's office.

Public health·2023

Same author

Behavioral and physiological responses to an inspired-air supplemental cooling system for dairy cows in free-stall housing.

Animal : an international journal of animal bioscience·2023

Same author

Truncation of <i>MAT1-2-7</i> Deregulates Developmental Pathways Associated with Sexual Reproduction in Huntiella omanensis.

Microbiology spectrum·2022

Same author

One key to fit all locks? Routine internal drainage to minimize seromas during thigh lift surgeries.

Annales de chirurgie plastique et esthetique·2022

Same author

Development of a novel stall design for dairy cattle: Part II. The effect of minimal stall partitioning on lying behavior, rumination, stall cleanliness, and preference.

Animal : an international journal of animal bioscience·2022

Same author

Development of a novel stall design for dairy cattle: Part I. The effect of an increased slope on lying behavior, rumination, cleanliness, and preference.

Animal : an international journal of animal bioscience·2022

Search research articles

Video Experimental Relacionado

Updated: Jul 14, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Diferencias en la biodisponibilidad pulmonar entre diferentes propulsores para el propionato de fluticasona.

A M Wilson, E J Sims, L C Orr

Lancet (London, England)

|October 26, 1999

Resumen

Cambiar los inhaladores de propionato de fluticasona puede ser arriesgado. Las formulaciones más nuevas de hidrofluoroalcanos muestran una menor biodisponibilidad pulmonar que las más antiguas de clorofluorocarbonos, lo que podría afectar la efectividad del tratamiento.

Más Videos Relacionados

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

Intratracheal Administration of Dry Powder Formulation in Mice

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

Videos de Experimentos Relacionados

Last Updated: Jul 14, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

Intratracheal Administration of Dry Powder Formulation in Mice

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

Área de la Ciencia:

Farmacología Farmacología.
Medicina de las vías respiratorias.
Sistemas de suministro de drogas Sistemas de suministro de drogas.

Sus antecedentes:

El propionato de fluticasona es un corticosteroide inhalado ampliamente utilizado para afecciones respiratorias.
Las formulaciones anteriores del inhalador utilizaban clorofluorocarbonos (CFC) como propulsores.
Las formulaciones actuales utilizan predominantemente hidrofluoroalcanos (HFA) como propulsores debido a las regulaciones ambientales.

Objetivo del estudio:

Para comparar la biodisponibilidad pulmonar del propionato de fluticasona entre las formulaciones de inhaladores basadas en CFC y HFA.
Evaluar las implicaciones clínicas del cambio entre estos diferentes tipos de inhaladores.

Principales métodos:

La biodisponibilidad pulmonar se evaluó indirectamente mediante la medición de la supresión suprarrenal, un efecto farmacodinámico conocido del propionato de fluticasona absorbido sistémicamente.
Los pacientes o los detalles del diseño del estudio no se especificaron en el resumen.

Principales resultados:

La biodisponibilidad pulmonar, indicada por la supresión suprarrenal, fue aproximadamente dos veces mayor con la formulación de propelente de clorofluorocarbono (CFC) en comparación con la formulación de propelente de hidrofluoroalcano (HFA).
Esto sugiere que significativamente menos fármaco llega a los pulmones con la formulación HFA.

Conclusiones:

Cambiar directamente entre las formulaciones de inhaladores de propionato de fluticasona en una base equivalente a microgramos puede no ser aconsejable debido a diferencias significativas en la biodisponibilidad pulmonar.
Los pacientes y los proveedores de atención médica deben ser conscientes de los posibles problemas de equivalencia terapéutica al cambiar de tipo de inhalador.
Es posible que se necesiten estudios adicionales para establecer ajustes de dosis apropiados al cambiar de formulaciones de CFC a HFA.